Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Simple Summary Immune escape mechanisms have been identified in every step of lung
tumorigenesis. A heterogeneous ensemble of immune evasion processes shapes the …

Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …

Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

It was reported that PD-L1 expression was correlated with genetic alterations. Whether PD-
L1 was regulated by mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) in non …

Introduction Immune escape frequently occurs and restricts the durability of the antitumor
immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death …

Abstract Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade
has been approved as the standard-of-care for the treatment of non-small cell lung cancer …

Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death
ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell …

Cancer immunotherapy (CIT) has transformed cancer treatment. In particular,
immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 …

ABSTRACT Programmed death-ligand 1 (PD-L1) is an inhibitory ligand that binds to PD-1 to
suppress T cell activation. PD-L1 is constitutively expressed and inducible in tumor cells, but …